ADC Therapeutics SA Operating Expense
ADC Therapeutics SA (ADCT) reported Operating Expense of $51.90 million for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:OperatingExpense · last filed 2023-11-07
- ADC Therapeutics SA operating expense for the quarter ending 2023-09-30 was $51.90M, a 34.67% decline year-over-year.
- ADC Therapeutics SA operating expense for the quarter ending 2023-06-30 was $59.07M, a 31.87% decline year-over-year.
- ADC Therapeutics SA operating expense for the quarter ending 2023-03-31 was $70.56M, a 18.76% decline year-over-year.
- ADC Therapeutics SA operating expense for the quarter ending 2022-12-31 was $80.54M, a 0.93% increase year-over-year.
| Period end | Operating Expense 3 month | Operating Expense 6 month | Operating Expense 9 month | Operating Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $51.90M 6-K · filed 2023-11-07 | $110.97M derived: sum of 2 quarters · filed 2023-11-07 | $181.53M 6-K · filed 2023-11-07 | $262.07M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $59.07M 6-K · filed 2023-08-08 | $129.64M 6-K · filed 2023-08-08 | $210.17M derived: sum of 3 quarters · filed 2023-08-08 | $289.61M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $70.56M 6-K · filed 2023-05-09 | $151.10M derived: sum of 2 quarters · filed 2023-05-09 | $230.53M derived: sum of 3 quarters · filed 2023-11-07 | $317.24M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $80.54M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $159.97M derived: sum of 2 quarters · filed 2023-11-07 | $246.67M derived: sum of 3 quarters · filed 2023-11-07 | $333.54M 20-F · filed 2023-03-15 |
| 2022-09-30 | $79.44M 6-K · filed 2023-11-07 | $166.14M derived: sum of 2 quarters · filed 2023-11-07 | $253.00M 6-K · filed 2023-11-07 | $332.79M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $86.70M 6-K · filed 2023-08-08 | $173.56M 6-K · filed 2023-08-08 | $253.35M derived: sum of 3 quarters · filed 2023-08-08 | $324.29M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $86.86M 6-K · filed 2023-05-09 | $166.65M derived: sum of 2 quarters · filed 2023-05-09 | $237.59M derived: sum of 3 quarters · filed 2023-05-09 | $311.83M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $79.79M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $150.73M derived: sum of 2 quarters · filed 2023-03-15 | $224.97M derived: sum of 3 quarters · filed 2023-03-15 | $295.64M 20-F · filed 2023-03-15 |
| 2021-09-30 | $70.94M 6-K · filed 2022-11-08 | $145.18M derived: sum of 2 quarters · filed 2022-11-08 | $215.85M 6-K · filed 2022-11-08 | $293.85M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $74.24M 6-K · filed 2022-08-09 | $144.91M 6-K · filed 2022-08-09 | $222.91M derived: sum of 3 quarters · filed 2023-03-15 | $275.34M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $70.67M 6-K · filed 2022-05-09 | $148.67M derived: sum of 2 quarters · filed 2023-03-15 | $201.09M derived: sum of 3 quarters · filed 2023-03-15 | $246.04M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $78.00M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $130.43M derived: sum of 2 quarters · filed 2023-03-15 | $175.38M derived: sum of 3 quarters · filed 2023-03-15 | $219.26M 20-F · filed 2023-03-15 |
| 2020-09-30 | $52.43M 6-K · filed 2021-11-02 | $97.38M derived: sum of 2 quarters · filed 2021-11-02 | $141.26M 6-K · filed 2021-11-02 | |
| 2020-06-30 | $44.95M 6-K · filed 2021-08-03 | $88.83M 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $43.88M 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $121.74M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $127.08M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |